Literature DB >> 125803

Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate.

P C Walsh, P K Siiteri.   

Abstract

Spironolactone, an inhibitor of androgen synthesis, has been administered to castrated men with metastatic carcinoma of the prostate. Plasma levels of testosterone, androstenedione and dehydroepiandrosterone were significantly decreased. These data indicate that spironolactone suppresses adrenal androgen production and suggest that it may be of benefit in the treatment of orchiectomized patients with advanced carcinoma of the prostate.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 125803     DOI： 10.1016/s0022-5347(17)67001-0

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


  12 in total

1.  Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate.

Authors:  Santhanam Sundar; Peter D Dickinson
Journal:  BMJ Case Rep       Date:  2012-02-25

Review 2.  Update in cancer chemotherapy: genitourinary tract cancer, Part 3: Cancer of the prostate.

Authors:  J C Wright
Journal:  J Natl Med Assoc       Date:  1988-03       Impact factor: 1.798

3.  Contrasting effects of eplerenone and spironolactone on adrenal cell steroidogenesis.

Authors:  P Ye; T Yamashita; D M Pollock; H Sasano; W E Rainey
Journal:  Horm Metab Res       Date:  2008-09-25       Impact factor: 2.936

Review 4.  Targeting the renin-angiotensin-aldosterone system in heart failure.

Authors:  Chim C Lang; Allan D Struthers
Journal:  Nat Rev Cardiol       Date:  2013-01-15       Impact factor: 32.419

Review 5.  Hormonal therapy for stage D cancer of the prostate.

Authors:  M R Gudziak; A Y Smith
Journal:  West J Med       Date:  1994-04

6.  Pharmacia Award 1990. The biological significance of low testosterone levels and of adrenal androgens in transplantable prostate cancer lines.

Authors:  W M van Weerden; A van Kreuningen; E P Moerings; F H de Jong; G J van Steenbrugge; F H Schröder
Journal:  Urol Res       Date:  1991

7.  A study of the capacity for regeneration of rat and human Leydig cells.

Authors:  T Senge; B Schenck; U Tunn; T Hülshoff; F Neumann
Journal:  Urol Res       Date:  1978

8.  Phase II trial and pharmacokinetic assessment of intravenous melphalan in patients with advanced prostate cancer.

Authors:  D C Smith; D I Jodrell; M J Egorin; R M Ambinder; E G Zuhowski; W Kreis; P G Ellis; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism.

Authors:  M Messina; C Manieri; P Biffignandi; C Massucchetti; R F Novi; G M Molinatti
Journal:  J Endocrinol Invest       Date:  1983-02       Impact factor: 4.256

10.  Effects of repeated administration of potassium canrenoate (SC-14266) on serum gonadotrophin, prolactin, testosterone and progesterone in male rats.

Authors:  T Muraki; T Nakadate; K Kubota; Y Tokunaga; R Kato
Journal:  Experientia       Date:  1980-06-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.